Our lab was selected by PROLIFIC—the Prognostic Lung Fibrosis Consortium—to develop biomarkers in support of new therapies for idiopathic pulmonary fibrosis (IPF). Our Protein Biomarkers lab—then known as Rules-Based Medicine—developed validated and 11 blood-based biomarkers for IFP using published data on potential prognostic markers.
These validated Luminex-based biomarkers can be used to support your IPF trials, with demonstrated utility in characterizing:
- Epithelial damage (CA 125, CYFRA 21-1, SP-D, CA-19-9, KL-6),
- Fibrosis (MMP-7, Tenascin C),
- Inflammation (CCL18, CXCL13, slCAM1),
- Thrombosis (PAI-1)
A portion of the biomarkers we developed are being utilized in the PROLIFIC Risk Score, which is currently under review by the FDA’s Center for Drug Evaluation and Research through its Biomarker Qualification Program.
Scientific Poster
Development of a Multi-biomarker Risk Score based on Serum Proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)
Our work was featured in a poster presented at the IPF (Idiopathic Pulmonary Fibrosis) Summit in August 2025.
The poster—Development of a Multi-biomarker Risk Score based on Serum Proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)—highlights our work in developing a suite of IPF assays used by leading pharmaceutical companies within the consortium.
|
IPF1 |
IPF2 |
IPF3 | IPF4 | IPF5 |
| ICAM-1 | CA-125 | BLC | MMP-7 | CA-19-9 |
| KL-6 | CYFRTA 21-1 | |||
| PAI-1 | ||||
| PARC | ||||
| SP-D | ||||
| TN-C |
Related Resources
Explore Our Solutions
Discover how IQVIA's comprehensive suite of solutions can help you navigate the complexities of healthcare and accelerate innovation.
